Avantor is a chemical company that was acquired by private equity company New Mountain Capital in 2010 from Covidien. It is looking to raise $4.4bn at around $19.50 a share, the price range of the IPO being between $18-$21.
The company provides services and products in education, healthcare and biopharma and while it appears to have seen decent revenue growth, $5.8bn in 2018, largely due to acquisitions, it hasn’t made a profit in the last three years.
The proceeds of the IPO won't be going to grow the business, but to the investors who have loaded the company with up to $6.9bn in debt, more than the company's total revenues for its last tax year, and any previous tax year for that matter.
This ought to be a red flag; typically these types of fund raisings should look to enhance the value of the business, or at least reduce the burden of the company’s debt.
This IPO does nothing of the sort, and appears only to be enriching its owners, which should make any prospective investor a little bit nervous.
Let’s see if they are equally discerning about this particular one.
Disclaimer: CMC Markets is an order execution-only service. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.